Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Pfizer ends Sutent trial in breast cancer

Pfizer Inc. (NYSE:PFE) ended the Phase III SUN 1107 trial to treat advanced

Read the full 138 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE